Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. (Q47828375)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 April 2009

edit

Language	Label	Description	Also known as
English	Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis.	scientific article published on 29 April 2009

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19432937

retrieved

6 February 2018

reference URL

http://europepmc.org/abstract/MED/19432937

title

Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19432937

retrieved

6 February 2018

reference URL

http://europepmc.org/abstract/MED/19432937

main subject

immunotherapy

1 reference

based on heuristic

inferred from title

author name string

K Kontou-Fili

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19432937

retrieved

6 February 2018

reference URL

http://europepmc.org/abstract/MED/19432937

C I Filis

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19432937

retrieved

6 February 2018

reference URL

http://europepmc.org/abstract/MED/19432937

publication date

29 April 2009

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19432937

retrieved

6 February 2018

reference URL

http://europepmc.org/abstract/MED/19432937

published in

Allergy

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19432937

retrieved

6 February 2018

reference URL

http://europepmc.org/abstract/MED/19432937

volume

64

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19432937

retrieved

6 February 2018

reference URL

http://europepmc.org/abstract/MED/19432937

issue

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19432937

retrieved

6 February 2018

reference URL

http://europepmc.org/abstract/MED/19432937

page(s)

1384-1385

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19432937

retrieved

6 February 2018

reference URL

http://europepmc.org/abstract/MED/19432937

Identifiers

DOI

10.1111/J.1398-9995.2009.02045.X

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19432937

retrieved

6 February 2018

reference URL

http://europepmc.org/abstract/MED/19432937

PubMed publication ID

19432937

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19432937

retrieved

6 February 2018

reference URL

http://europepmc.org/abstract/MED/19432937

ResearchGate publication ID

24418480

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47828375&oldid=1233703400"